Comparison of Breast Cancer 3-years Survival Rate Based on the Pathological Stages

Mursyidah, Nur Imroatul; Ashariati, Ami; Kusumastuti, Etty Hary

doi:10.20473/juxta.v10i12019.38-43

Cited by 4 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The limited study is known to observe survival for each stage IIIA, IIIB, and IIIC. Mursyidah et al [30] observed that the 5-year overall survival for stage IIIA, IIIB, and IIIC, respectively, were 71.4%, 53.8%, and 50%. The problem of inadequate local healthcare providers, therapeutic facilities, and accessibility to healthcare centers in Indonesia may explain the high number of advanced-stage (IIIB-IIIC) patients which may lower the overall survival in this study [6,10,24].…”

Section: Discussionmentioning

confidence: 99%

Overall Survival for Stage III Breast Cancer Patients at DR. Mohammad Hoesin General Hospital Palembang and the Influencing Factors

Deanasa

Umar

Fitri

2022

Indonesian Journal of Cancer

View full text Add to dashboard Cite

Background: There is still a limited number of studies related to overall survival in breast cancer patients in Indonesia. This study determines the overall survival and the factor which can affect the survival of stage III breast cancer patients.Methods: This study was a retrospective study. Patients first diagnosed with stage III breast cancer from January 1 to August 31, 2018, at DR. Mohammad Hoesin General Hospital Palembang had been studied. The primary outcome of this study was overall survival. The sociodemographic, clinicopathology, and treatment factors were analyzed to identify the independent variables associated with overall survival using Kaplan-Meier and Cox proportional hazard regression.Results: In this study, 78 samples were included. The 3-year overall survival for stage III breast cancer was 71%. In the bivariate analysis, several factors including older age (> 40) (HR = 2.795, 95% CI 1.223–6.387), higher stages for IIIB (HR = 7.155, 95% CI 0.960–53.334), and IIIC (HR = (HR = 33.450, 95% CI 3.013-371.354), history of not undergoing surgical intervention (HR = 3.999, 95% CI 1.684–9.495), and adjuvant chemotherapy (HR = 2.768, 95% CI 1.211–6.327) have been associated significantly to lower overall survival. Multivariate analysis showed IIIC breast cancer stage as an independent factor and had a significantly increased probability of mortality (HR = 14.677, 95% CI 1.268–169.948).Conclusions: The stage at diagnosis was the only significant predictor for the survival outcome, indicating that early diagnosis may need more attention.

show abstract

Section: Discussionmentioning

confidence: 99%

Overall Survival for Stage III Breast Cancer Patients at DR. Mohammad Hoesin General Hospital Palembang and the Influencing Factors

Deanasa

Umar

Fitri

2022

Indonesian Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…21 The lower-stage breast cancer patients had the best 3-year survival rates compared to the end-stage breast cancer patients. 22 This study examined 30 breast cancer patients who underwent CAF chemotherapy for three cycles to obtain a total of 90 cycles. Of the 30 patients, 24 people (80%) had neutropenia and 6 (20%) without neutropenia.…”

Section: Methodsmentioning

confidence: 99%

Post-Chemotherapy Monocytopenia as a Predictor of Chemotherapy – Induced Neutropenia in Breast Cancer Patients

2022

View full text Add to dashboard Cite

Background: Chemotherapy-induced neutropenia (CIN) is chemotherapy's most frequent myelosuppression effect. Previous studies have examined static prognostic factors to assess dynamic neutrophil changes in each cycle. This study focuses on post-chemotherapy monocytopenia as a more dynamic predictor of CIN. This research aimed to know whether post-chemotherapy monocytopenia can be used as a predictor of CIN in breast cancer patients undergoing the chemotherapy cycle. Methods: This research used a prospective and a retrospective longitudinal cohort of breast cancer patients undergo a CAF regimen at Sanglah Hospital Denpasar. The research was conducted on 30 samples for three cycles (90 total cycles). Monocyte data is taken in the first week (days 4 to 9), and neutrophil data is taken in the second week (days 10 to 16). Results: From statistical analysis with interval data scale, we obtained that p 0.001 with Pearson correlation 0.613 for cycle 1, p 0.001 with Pearson correlation 0.611 for cycle 2, and p 0.003 with Pearson correlation 0.522 for cycle 3. Conclusions: In conclusion, post-chemotherapy monocytopenia can be used to predict the occurrence of chemotherapy-induced neutropenia (CIN) with the strongest positive correlation in the first cycle.

show abstract

“…Despite substantial advances in breast cancer research over the last 20 years, a large proportion of patients will acquire metastatic illness. Unfortunately, metastatic breast cancer has not yet been cured [ 5 ]. TNM stage, histopathological type, histological grade, hormone receptors, and the number of mitotic pictures are prognostic variables that affect the survival of breast cancer patients, according to the consensus of the College of American Pathologists in 1999.…”

Section: Introductionmentioning

confidence: 99%

“…It ranges from stage I to stage IV. Stage III cancer has a 5-year life expectancy of 86 %, and it changes with each stage [ [5] , [6] , [7] ].…”

Section: Introductionmentioning

confidence: 99%

Neoadjuvant chemotherapy response, disease-free survival, and overall survival of breast cancer in a single institution

Prihantono

2023

Surgery Open Science

View full text Add to dashboard Cite

Comparison of Breast Cancer 3-years Survival Rate Based on the Pathological Stages

Cited by 4 publications

References 10 publications

Overall Survival for Stage III Breast Cancer Patients at DR. Mohammad Hoesin General Hospital Palembang and the Influencing Factors

Overall Survival for Stage III Breast Cancer Patients at DR. Mohammad Hoesin General Hospital Palembang and the Influencing Factors

Post-Chemotherapy Monocytopenia as a Predictor of Chemotherapy – Induced Neutropenia in Breast Cancer Patients

Neoadjuvant chemotherapy response, disease-free survival, and overall survival of breast cancer in a single institution

Contact Info

Product

Resources

About